New post-market registry data shows that the first two FDA-approved cardiac rhythm management devices without transvenous leads are performing about as well as could be hoped in the "real world."
At the Heart Rhythm Society Scientific Sessions in Chicago on May 11, Mikhael El-Chami of Emory University in Atlanta reported...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?